Mean intravenous and oral plasma clearance data, number of subjects, blood/plasma ratios, and fraction unbound in plasma for drugs investigated
References for all the clinical data are listed in the supplemental data.
| Observed In Vivo Plasma Clearancea | RBb | fup | No. Subjects | |||
|---|---|---|---|---|---|---|
| Intravenous | Oral | Intravenous | Oral | |||
| ml · min−1 · kg−1 | ||||||
| Quercetin | 5.2 (0.6–12) | 391 (1.55–62381) | 1 | 0.01 | 10 | 46 |
| Raloxifene | 14.7c | 735 (735–831) | 1 | 0.05 | N.A. | >1000 |
| Salbutamol | 8.4 (7.6–9.3) | 16.6 (12.6–22.9) | 1 | 0.925 | 48 | 51 |
| Troglitazone | 2.5 | 12.8 (5.3–14.6) | 0.55 | 0.01 | N.A. | >250 |
N.A., no subject information available.
↵a Data are weighted mean (range). For salbutamol, weighted renal clearance was 4.8 and 4.3 ml · min−1 · kg−1 after intravenous and oral administration, respectively. Renal clearance was negligible for other drugs.
↵b Assumed to be 1 for basic drugs and 0.55 for acidic drugs.
↵c Calculated from oral clearance data (735 ml · min−1 · kg−1) and reported bioavailability of 2% (Hochner-Celnikier, 1999; Mizuma, 2009).